Smith & Nephew plc (NPW1.F)
| Previous close | 11.18 |
| Open | 11.15 |
| Bid | 11.15 x 300000 |
| Ask | 11.39 x 300000 |
| Day's range | 11.15 - 11.15 |
| 52-week range | 10.21 - 15.18 |
| Volume | |
| Avg. volume | 88 |
| Market cap | 9.84B |
| Beta (5Y monthly) | 0.51 |
| PE ratio (TTM) | 39.82 |
| EPS (TTM) | 0.28 |
| Earnings date | N/A |
| Forward dividend & yield | 0.35 (3.14%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | N/A |
Globe NewswireSmith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal,1 that shows a novel mechanism of action relating to pressure injury prevention (PIP). The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a layer-on-layer sliding phenomenon occurs and allows for dissip
Fool.co.ukDown 27%, but set for major growth, this hidden FTSE gem looks cheap to me
This powerhouse FTSE stock has embarked on a new growth strategy that’s already showing good results, but it looks undervalued to me. The post Down 27%, but set for major growth, this hidden FTSE gem looks cheap to me appeared first on The Motley Fool UK.
GlobeNewswireSmith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia
Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announced an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT™ in Australia during the recent Australian Orthopedics Association COE Meeting in Sydney. A single-use, sterile navigation system with everything provided in a small carton, NAVBIT SPRINT™ is designed to suit busy surgeons -
